{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=56",
    "query": {
      "condition": "Leukemia, Myelogenous, Acute",
      "page": 56
    },
    "page_size": 10
  },
  "pagination": {
    "page": 56,
    "page_size": 10,
    "total_count": 2504,
    "total_pages": 251,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=57&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=55&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T16:50:34.634Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01024127",
      "title": "Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adult Acute Myeloid Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 2500,
      "start_date": "2009-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-05-18",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024127"
    },
    {
      "nct_id": "NCT02632721",
      "title": "A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "BI 836858",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2016-06-16",
      "completion_date": "2023-01-16",
      "has_results": true,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Chicago, Illinois • Lake Success, New York + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02632721"
    },
    {
      "nct_id": "NCT06652438",
      "title": "Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia, Adult"
      ],
      "interventions": [
        {
          "name": "Revumenib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stichting Hemato-Oncologie voor Volwassenen Nederland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2025-05-05",
      "completion_date": "2032-08-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Francisco, California • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06652438"
    },
    {
      "nct_id": "NCT01550185",
      "title": "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Basophilic Leukemia",
        "Adult Acute Eosinophilic Leukemia",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Recurrent Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "eltrombopag olamine",
          "type": "DRUG"
        },
        {
          "name": "standard follow-up care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-05",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Buffalo, New York",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01550185"
    },
    {
      "nct_id": "NCT03194685",
      "title": "Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML, Adult"
      ],
      "interventions": [
        {
          "name": "FF-10101-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fujifilm Pharmaceuticals U.S.A., Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2017-05-05",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03194685"
    },
    {
      "nct_id": "NCT04203316",
      "title": "Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Enasidenib",
          "type": "DRUG"
        },
        {
          "name": "Enasidenib Mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "24 Months to 21 Years"
      },
      "enrollment_count": 1,
      "start_date": "2023-08-14",
      "completion_date": "2026-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04203316"
    },
    {
      "nct_id": "NCT01499147",
      "title": "Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Leukemia",
        "Chronic Myelogenous Leukemia",
        "Malignant Lymphoma",
        "Hodgkin's Disease",
        "Multiple Myeloma",
        "Lymphocytic Leukemia",
        "Myeloproliferative Disorder",
        "Polycythemia Vera",
        "Myelofibrosis",
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "fludarabine/busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine/ melphalan",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "10 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2000-02",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01499147"
    },
    {
      "nct_id": "NCT00368355",
      "title": "T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Non Hodgkins Lymphoma",
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia",
        "Hemophagocytic Lymphohistiocytosis (HLH)",
        "Familial Hemophagocytic Lymphohistiocytosis (FLH)",
        "Viral-associated Hemophagocytic Syndrome (VAHS)",
        "X-linked Lymphoproliferative Disease (XLP)"
      ],
      "interventions": [
        {
          "name": "Ara-C",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Campath-1H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem Cell Infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2000-04",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368355"
    },
    {
      "nct_id": "NCT01721876",
      "title": "Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Volasertib",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 666,
      "start_date": "2013-01-29",
      "completion_date": "2021-05-28",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Duluth, Minnesota • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Duluth",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721876"
    },
    {
      "nct_id": "NCT05829226",
      "title": "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML, Adult Recurrent",
        "MDS"
      ],
      "interventions": [
        {
          "name": "LYT-200",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PureTech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2022-12-12",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-24T16:50:34.634Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05829226"
    }
  ]
}